The RNA therapeutics market is projected to grow from USD 13.7 billion in 2023 to USD 18.0 billion by 2028 at a CAGR of 5.6%. RNA therapeutics have diverse abilities to target the desired protein/gene, and the ongoing research in RNA modification and delivery systems has helped in developing unique RNA-based formulations. As of 2022, the use of RNA therapeutics is approved for indications such as COVID-19, hemophilia A and B, cholesterol reduction, spinal muscular atrophy (SMA), polyneuropathy of hereditary transthyretin-mediated amyloidosis-(ATTR), and familial chylomicronaemia syndrome (FCS).
The global RNA therapeutics market is a consolidated market, with Moderna, Inc. (US), Alnylam Pharmaceuticals, Inc. (US), and Pfizer Inc. (US) together accounting for the majority share of the global market. Novartis AG (Switzerland), Ionis Pharmaceuticals, Inc. (US), Sarepta Therapeutics, Inc. (US), and Sanofi (France), Arrowhead Pharmaceuticals, Inc. (US), BioNTech SE (Germany), Orna Therapeutics (US), CRISPR Therapeutics (Switzerland), Silence Therapeutics (UK), Astellas Pharma Inc. (Japan), CureVac SE (Germany), Sirnaomics (US), Arcturus Therapeutics Inc. (US) and Arbutus Biopharma (US).
To know about the assumptions considered for the study download the pdf brochure
Moderna, Inc. (US) Moderna, Inc. is one of the leading players in the RNA therapeutics market that has gained a prominent position in the vaccine space. The company’s COVID-19 booster vaccine—Spikevax—is well received globally and has shown considerable growth in sales after its approval in 2020. Additionally, it has built a strong pipeline for other mRNA-based vaccines, with a majority in the late clinical stage. Approval and EUA for its BA.4/BA.5 Omicron-targeting bivalent COVID-19 booster vaccine across various countries has also created a strong revenue stream for the company in 2022.
The company has focused on collaborations and strategic co-developments to strengthen its vaccine manufacturing capabilities. In March 2023, it collaborated with Generation Bio Co. to co-develop genetic medicines. This strategic collaboration combines Moderna's expertise in mRNA vaccines/therapy with Generation Bio's non-viral genetic medicine platform. In February 2023, the company also collaborated with Life Edit Therapeutics Inc., an ElevateBio company with expertise in next-generation gene editing technologies, to develop in vivo mRNA gene editing therapies.
Alnylam Pharmaceuticals, Inc. (US) Alnylam Pharmaceuticals offers three established RNAi therapies, namely, ONPATTRO (patisiran), GIVLAARI (givosiran), and OXLUMO (lumasiran)—all these therapies have shown consistent growth in sales from 2019 to 2022, thereby, contributing to Alnylam’s market position. The company has also recently added AMVUTTRA (vutrisiran) to its portfolio, which was approved in June 2022; the therapy recorded sales of approximately USD 90 million in the same year. The company has established itself as a prominent player in the RNAi therapeutics space, targeted toward ATTR treatment. The company focuses on partnerships and collaborations to expand its reach across different geographies. It partners with biotechnology and pharmaceutical companies to strengthen their development and manufacturing capabilities.
Novartis AG (Switzerland) Novartis presently offers only one product in the RNA therapeutics market named Leqvio (inclisiran), which is the only small-interfering RNA that is commercialized for cholesterol reduction. The company has developed this product through its collaboration with Alnylam Pharmaceuticals, Inc., offering the company a competitive edge in the market. The product reportedly reached a revenue of around USD 500 million in 2022 globally, providing a good head start to Novartis in the RNA therapeutics market. In 2022, just eleven months after it was launched, Leqvio was covered at or near the label for 76% of patients. It has also been assigned a unique Healthcare Common Procedure Coding System Code (J-code).
RNA Therapeutics Market by Product (Vaccines, Drugs), Type (mRNA Therapeutics, RNA Interference, Antisense Oligonucleotides), Indication (Infectious Diseases, Rare Genetic Diseases), End User (Hospitals & Clinics) - Global Forecast to 2028
Mr. Aashish Mehra
630 Dundee Road
Northbrook, IL 60062
USA : 1-888-600-6441
This FREE sample includes market data points, ranging from trend analyses to market estimates & forecasts. See for yourself.SEND ME A FREE SAMPLE